CMS Establishes Unique J-Code for Eagle Pharmaceuticals’ PEMFEXY™ (Pemetrexed for Injection)

On July 9, 2020 Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ: EGRX) reported that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing code for PEMFEXY (pemetrexed for injection) (Press release, Eagle Pharmaceuticals, JUL 9, 2020, View Source [SID1234561802]). This new Healthcare Common Procedure Coding System (HCPCS) code, or J-code, is J9304 (Injection, pemetrexed (PEMFEXY), 10 mg). The J-code will become effective on October 1, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new HCPCS code provides coding clarity to outpatient facilities and physicians who will administer PEMFEXY, facilitating access for patients and reimbursement from Medicare, Medicaid and commercial insurance.

In February 2020, Eagle received final approval of its New Drug Application (NDA) from FDA for PEMFEXY, a branded alternative to ALIMTA, following settlement of patent litigation with Eli Lilly and Company. The Company is entitled to initial market entry (equivalent to approximately a three-week supply of current ALIMTA utilization) on February 1, 2022, and a subsequent uncapped entry on April 1, 2022.

The Company also received a supplement approval from FDA for a 500mg multiple-dose vial of PEMFEXY on June 18, 2020.

About PEMFEXY

PEMFEXY is a pemetrexed injection ready-to-dilute formulation for locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with cisplatin; locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as maintenance treatment; locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy as a single agent; and malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery in combination with cisplatin.

New $3.7M grant to support research exploring mysterious link between cancer, HIV/AIDS

On July 9, 2020 Case Western Reserve University Research reported that it has found that those living with HIV have a higher risk for certain kinds of cancers—such as lung cancer (Press release, Case Western Reserve University, JUL 9, 2020, View Source [SID1234561779]). Now, with a new five-year, $3.7 million grant from the National Cancer Institute (NCI), researchers from Case Western Reserve University hope to find out why.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ge Jin, professor at the School of Dental Medicine and co-principal investigator on the research team, called the phenomenon "a mystery."

There are more than an estimated 1.7 million people newly infected with HIV every year, according to the U.S. Department of Health and Human Services. That’s 1.7 million people who are more likely to get cancer—and get it at an earlier age and at a higher frequency—than 1.7 million people who do not have HIV, Jin said.

"We want to look at the molecular events involved in these processes, and find out why," he said. "We need to find a better way to detect cancer in these patients at an earlier stage."

Jin is partnering with co-principal investigator Bingcheng Wang, the John A. and Josephine B. Wootton Endowed Chair of Research and Professor at the School of Medicine, who’s also a researcher at MetroHealth System. They found that the immune cells from HIV patients secrete exosomes—think tiny nanoparticles—and attack lung cells, thus promoting the growth of cancer.

Wang said he believes that grant from NCI will "further investigate this novel mechanism of lung cancer promotion by HIV and develop new therapeutic agents to treat the disease among people living with HIV."

HIV patients with lung cancer have a worse prognosis than those in the general population, multiple studies have shown. Previous research has shown certain remedies can neutralize the effects of the exosomes, also known as vesicles.

However, the causes for increased lung cancer among people living with HIV remain elusive.

The prevailing belief has been that those with HIV have weakened immune systems, but it’s not that simple, Jin said.

"If you’re living with HIV, the virus is arrested­—it’s kept at bay," he said. "That’s why the disease doesn’t manifest itself to become AIDS. It’s why those with HIV can live normal, healthy lives. There’s something else going on at the cellular level."

Jin said the new research will further explore potential causes—and remedies. He called his laboratory at the School of Dental Medicine "a pioneer" in the field of identifying exosomes in the blood of HIV patients promoting the growth of oral cancer cells.

"This is a very exciting project, as our investigation will help understand how lung cancer progresses in people living with HIV, which will potentially assist clinicians to assess risk factors of cancers and better treatment in the population," he said.

Indapta Therapeutics Provides Corporate Update

On July 9, 2020 Indapta Therapeutics, Inc., a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf, non-engineered, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple cancers, reported an update on its progress in advancing the development of its programs (Press release, Indapta Therapeutics, JUL 9, 2020, View Source [SID1234561803]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Since we emerged from stealth mode in January and announced our founding management team, scientific advisors and strategic partnership with Lonza, we have made substantial progress in advancing our next-generation, off-the-shelf, allogeneic immuno-oncology therapy," said Guy DiPierro, founder and chief executive officer of Indapta Therapeutics. "We have achieved several preclinical, regulatory and manufacturing milestones for our G-NK program, all of which are helping us move our novel program forward towards an IND submission and the initiation of a first-in-human trial in summer 2021."

Recent Program Updates

Presented data from its G-NK cell therapy program in a poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting II in June. In the preclinical study, clinical models injected with human multiple myeloma cells were treated with a monoclonal antibody daratumumab or elotuzumab, which are FDA-approved for multiple myeloma, either alone or in combination with Indapta’s G-NK cells or comparator cells. In response, the G-NK cells demonstrated superior antibody-dependent cellular cytotoxicity (ADCC) and increased survival. G-NK cells show significantly enhanced expression of interferon-gamma (IFNγ) and tumor necrosis factor alpha (TNFα) compared with conventional natural killer (NK) cells.
Submitted a pre-Investigational New Drug (IND) briefing package to the U.S. Food and Drug Administration (FDA) for its G-NK cells. Indapta participated in a Type C meeting with the Agency and received written feedback outlining a clear and detailed roadmap for an IND application and for Chemistry, Manufacturing and Controls (CMC) activity.
Successfully completed the Stage 1 manufacturing transfer to Lonza, which conducted feasibility manufacturing runs at its Houston facility. Lonza will now initiate the next step of process development for the manufacturing of off-the-shelf, allogeneic G-NK cell therapy under current good manufacturing practices (cGMP) for use in the IND submission.
Indapta completed a persistence trial at the University of Houston which determined its G-NK cells remained in the body in both cryopreserved and frozen forms without any issues of functional exhaustion or phenotypic changes in vivo. Results demonstrated that Indapta’s cryopreserved G-NK cells remained in the body more than 26 times longer than cryopreserved conventional NK cells. Indapta also collected new data on cancer killing compounds including TNFα, IFNγ, CD107a, perforin and granzyme, all of which were expressed in higher amounts as a result of Indapta’s G-NK cell therapy.
Granted broad intellectual property protection through an exclusively-held patent related to manufacturing processes, G-NK cell selection and G-NK cell treatment used as a monotherapy and in combination with multiple compounds in multiple oncology and viral indications.
About Indapta’s G-NK Cell Therapy
Indapta Therapeutics is developing a universal, allogeneic G-NK cell therapy designed to substantially improve the cytotoxicity of monoclonal antibody therapy in multiple cancers. G-NK cells are a specific and potent subset of NK (natural killer) cells with specialized anti-tumor activity resulting from an epigenetic change, rather than engineering. Indapta has further enhanced G-NK cells via specific G-NK cell subset selection and its proprietary manufacturing process which, when combined, produce a G-NK cell therapy that demonstrates higher efficacy, persistence and enhanced cryopreservation.

When a monoclonal antibody binds to the tumor target and to Indapta’s G-NK cell therapy product, it initiates the release of dramatically more cancer killing compounds than conventional NK cells, allowing for increased efficacy and potentially less frequent dosing. Indapta’s off-the-shelf G-NK cell therapy is further differentiated from other NK cell therapies in that it is a cell banked product with low variability. In vivo studies have demonstrated the safety of Indapta’s G-NK cell therapy.

Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy

On July 9, 2020 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT819, an off-the-shelf allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies (Press release, Fate Therapeutics, JUL 9, 2020, View Source [SID1234561780]). FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, and is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy. The Company plans to initiate clinical investigation of FT819 for the treatment of patients with relapsed / refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The clearance of our IND application for FT819 is a ground-breaking milestone in the field of cell-based cancer immunotherapy. Our unique ability to produce CAR T cells from a clonal master engineered iPSC line creates a pathway for more patients to gain timely access to therapies with curative potential," said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. "Four years ago, we first set out under our partnership with Memorial Sloan Kettering led by Dr. Michel Sadelain to improve on the revolutionary success of patient-derived CAR T-cell therapy and bring an off-the-shelf paradigm to patients, and we are very excited to advance FT819 into clinical development."

FT819 was designed to specifically address several limitations associated with the current generation of patient- and donor-derived CAR T-cell therapies. Under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering, and Head, Gene Expression and Gene Transfer Laboratory at MSK, the Company incorporated several first-of-kind features into FT819 including:

Use of a clonal master iPSC line as the starting cell source, which enables CAR T cells to be mass produced and delivered off-the-shelf for broad patient access;
Incorporation of a novel 1XX CAR signaling domain, which has been shown to extend T-cell effector function without eliciting exhaustion in published work described in the journal Nature Medicine (View Source);
Insertion of the CAR transgene directly into the T-cell receptor alpha constant (TRAC) locus, which has been shown to promote uniform CAR expression and enhanced T-cell potency in published work described in the journal Nature (View Source); and
Complete bi-allelic disruption of T-cell receptor (TCR) expression for the prevention of graft-versus-host disease (GvHD), a potentially life-threatening complication associated with allogeneic T-cell therapy.
The multi-center Phase 1 clinical trial of FT819 is designed to determine the maximum tolerated dose of FT819 and assess its safety and clinical activity in up to 297 adult patients across three types of B-cell malignancies (CLL, ALL, and NHL). Each indication will enroll independently and evaluate three dose-escalating treatment regimens: Regimen A as a single dose of FT819; Regimen B as a single dose of FT819 with IL-2 cytokine support; and Regimen C as three fractionated doses of FT819. For each indication and regimen, dose-expansion cohorts of up to 15 patients may be enrolled to further evaluate the clinical activity of FT819.

At the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual 2020 Meeting, the Company presented preclinical data demonstrating FT819 is comprised of CD8αβ T cells with uniform 1XX CAR expression and complete elimination of endogenous TCR expression. Additionally, data from functional assessments showed FT819 has antigen-specific cytolytic activity in vitro against CD19-expressing leukemia and lymphoma cell lines that is comparable to that of healthy donor-derived CAR T cells, and persists and maintains tumor clearance in the bone marrow in an in vivo disseminated xenograft model of lymphoblastic leukemia.

Fate Therapeutics has an exclusive license for all human therapeutic use to U.S. Patent No. 10,370,452 pursuant to its license agreement with MSK1, which patent covers compositions and uses of effector T cells expressing a CAR, where such T cells are derived from a pluripotent stem cell including an iPSC. In addition to the patent rights licensed from MSK, the Company owns an extensive intellectual property portfolio that broadly covers compositions and methods for the genome editing of iPSCs using CRISPR and other nucleases, including the use of CRISPR to insert a CAR in the TRAC locus for endogenous transcriptional control.

1 Fate Therapeutics has licensed intellectual property from MSK on which Dr. Sadelain is an inventor. As a result of the licensing arrangement, MSK has financial interests related to Fate Therapeutics.

About Fate Therapeutics’ iPSC Product Platform
The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

Transgene and Hypertrust Patient Data Care Announce Successful Go-Live of the World’s First Blockchain Solution for Clinical Trials of Personalized Healthcare

On July 9, 2020 Transgene (Paris:TNG) and Hypertrust Patient Data Care reported as a world premiere the first productive blockchain solution for clinical trials of personalized healthcare, leveraging the Hypertrust X-Chain for Clinical Trials product (Press release, Transgene, JUL 9, 2020, View Source [SID1234561804]). The cloud-based solution monitors and orchestrates the supply chain processes of Transgene’s AI-enhanced TG4050 individualized therapeutic vaccine based on the myvac technology, against ovarian, head and neck cancer providing an immutable audit trail throughout the treatment process.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The innovative collaboration between Transgene and Hypertrust marks a milestone in the ongoing fight against cancer. The blockchain-based Hypertrust X-Chain solution supports Transgene’s personalized immunotherapies comprehensively, ensuring a trustworthy process in the background of the medical treatment. All emerging personalized treatments have a massive need for trustworthy and decentralized solutions, due to the strong cross-company collaborative nature of the production process.

Transgene’s first individualized immunotherapy product candidate is based on the myvac technology. It is currently evaluated in two ongoing clinical trials, including patients in Europe and in the USA. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) that are identified and selected using state-of-the-art artificial intelligence capabilities. myvac-based products are designed to stimulate the patient’s immune response, to recognize and destroy tumor cells based on their own mutations. This individualized immunotherapy is developed specifically for each patient.

"We have set up multiple collaborations around the world to allow each patient’s anticancer therapy to be designed in a timely manner. Blockchain technologies are a perfect tool to ensure that the patient’s genetic data are protected while ensuring that all the interventions of our partners are both smooth and tracked. We were very happy to collaborate with Hypertrust and together set up this novel process, demonstrating once again Transgene’s ability to be at the forefront of innovation", commented Eric Quéméneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer of Transgene.

"We are very proud to present with our partner Transgene the world’s first productive blockchain solution for clinical trials of personalized healthcare. The combination of Transgene’s innovative and AI-enhanced TG4050 cancer vaccine, combined with the security and workflow orchestration features of our platform provides the optimum support for a highly personalized cancer treatment process", says Andreas Göbel, CEO of Hypertrust Patient Data Care.

Especially in clinical trials of personalized healthcare there is an essential need for an immutable audit trail, which is created by different parties throughout the supply and production process. Blockchain technologies bring a high level of trust, as it allows a total transparency on how the data were modified throughout the process and provide additional protection in an age of increasing cyberthreats.

Hypertrust X-Chain for Clinical Trials by Hypertrust Patient Data Care is a market-leading solution for the orchestration and documentation of clinical trials for personalized healthcare. It ensures the chain of identity and custody for personalized treatments in the context of clinical trials. The decentralized platform leverages blockchain technology, to provide closed-loop supply chain monitoring and orchestration, based on a workflow process definition. The solution provides an immutable and tamper-proof audit trail of all recorded data throughout the treatment. Also, it allows the migration towards the commercial scale solution "X-Chain for Commercialized Treatments".